製品の概要

  • 製品名Anti-TGF beta 1 antibody
    TGF beta 1 一次抗体 製品一覧
  • 製品の詳細
    Chicken polyclonal to TGF beta 1
  • 特異性This product will recognise recombinant human TGF beta 1 and pTGF Beta 1.2 by various immunochemical techniques including neutralization, immunoblotting and ELISA. By immunoblotting and ELISA, the antibody shows less than 2 % crossreactivity with TGF Beta 2 and TGF Beta 3 and less than 15 % cross-reactivity with recombinant amphibian TGF Beta 5. Full length, inactive 44 kD TGFB1 is cleaved into mature TGFB1 (13 kD). TGFB1 also homodimerizes and heterodimerizes with TGFB2, so there is potential for multiple different band sizes in WB.
  • アプリケーション適用あり: Inhibition Assay, ELISA, WBmore details
  • 種交差性
    交差種: Human
  • 免疫原

    Recombinant full length protein (mature protein)(Human), expressed in CHO cells.

  • ポジティブ・コントロール

製品の特性

アプリケーション

Our Abpromise guarantee covers the use of ab10518 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
Inhibition Assay
ELISA
WB
  • 追加情報ELISA: For ELISAs, a working concentration of 0.5 to 1.0 µg/ml antibody is recommended. The detection limit for recombinant human TGF beta 1 is approximately 0.15 ng/well.
    WB: For immunoblotting, a working concentration of 0.1 to 0.2 µg/ml antibody is recommended. The detection limit for recombinant human TGF beta 1 is approximately 1 ng/lane and 5 ng/lane under non-reducing and reducing conditions, respectively. Predicted molecular weight: 47 kDa for the unprocessed precursor; 25 kDa for the mature protein.
    Inhib: Anti-Human TGF beta 1 neutralises the bioactivity of recombinant human TGF beta 1 by inhibiting cell proliferation using the IL4 dependent murine HT-2 cell line.

    In this bioassay, recombinant human TGF beta 1 (0.25 ng/ml) is preincubated with various cencentrations of the antibody (0.1 to 1000 ng/ml) for 1 hour at room temperature in a 96-well microtiter plate. Following this pre-incubation, HT-2 cells are added to each well. The total volume of 100 µl, containing antibody at various concentrations, recombinant mouse IL-4 at 7.5 ng/ml, recombinant human TGF-Beta-1 at 0.25 ng/ml, and HT-2 cells at 1 x 105 cells/ml, is incubated for 48 hours at 37 °C in a 5 % CO2 humidified incubator. 3H-thymidine is added during the final four hours. Cells are harvested onto glass filters and the 3H-thymidine incorporated into DNA is measured.

    The Neutralization Dose50 (ND50) for anti-human TGF beta 1 is approximately 5 to 10 ng/ml in the presence of 0.25 ng/ml of recombinant human TGF beta 1, using the murine HT-2 cell line. The ND50 of this antibody is defined as the concentration of antibody resulting in a one-half maximal inhibition of bioactivity of recombinant human TGF beta 1 that is present at a concentration just high enough to elicit a maximum response. The exact concentration of antibody required to neutralize recombinant human TGF beta 1 activity is dependent on the cytokine concentration, cell type, growth conditions, and the type of activity studied.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • ターゲット情報

    • 機能Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts.
    • 組織特異性Highly expressed in bone. Abundantly expressed in articular cartilage and chondrocytes and is increased in osteoarthritis (OA). Co-localizes with ASPN in chondrocytes within OA lesions of articular cartilage.
    • 関連疾患Defects in TGFB1 are the cause of Camurati-Engelmann disease (CE) [MIM:131300]; also known as progressive diaphyseal dysplasia 1 (DPD1). CE is an autosomal dominant disorder characterized by hyperostosis and sclerosis of the diaphyses of long bones. The disease typically presents in early childhood with pain, muscular weakness and waddling gait, and in some cases other features such as exophthalmos, facial paralysis, hearing difficulties and loss of vision.
    • 配列類似性Belongs to the TGF-beta family.
    • 翻訳後修飾Glycosylated.
      The precursor is cleaved into mature TGF-beta-1 and LAP, which remains non-covalently linked to mature TGF-beta-1 rendering it inactive.
    • 細胞内局在Secreted > extracellular space > extracellular matrix.
    • Information by UniProt
    • 参照データベース
    • 別名
      • CED antibody
      • DPD1 antibody
      • LAP antibody
      • Latency-associated peptide antibody
      • Prepro transforming growth factor beta 1 antibody
      • TGF beta 1 antibody
      • TGF beta antibody
      • TGF beta 1 protein antibody
      • TGF-beta 1 protein antibody
      • TGF-beta-1 antibody
      • TGF-beta-5 antibody
      • TGF-beta1 antibody
      • TGFB antibody
      • Tgfb-1 antibody
      • tgfb1 antibody
      • TGFB1_HUMAN antibody
      • TGFbeta antibody
      • TGFbeta1 antibody
      • Transforming Growth Factor b1 antibody
      • Transforming Growth Factor beta 1 antibody
      • Transforming growth factor beta 1a antibody
      • transforming growth factor beta-1 antibody
      • transforming growth factor, beta 1 antibody
      see all

    Anti-TGF beta 1 antibody (ab10518) 使用論文

    ab10518 has not yet been referenced specifically in any publications.

    Product Wall

    The immunogen was the mature protein. Please contact us again if you have any additional questions.

    I'm sorry to hear you are having problem with ab10518. I would like to suggest the following modifications to your protocol: -make sure your protease inhibitors are fresh when added to the lysis buffer -Use loading buffer made up with betamerc...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"